Dysphagia Therapy
Like No Other

Non-surgical, neurostimulation therapy
to restore swallowing control and reduce length of stay.

Dysphagia Therapy
Like No Other

Non-surgical, neurostimulation therapy
to restore swallowing control and reduce length of stay.

Dysphagia Therapy
Like No Other

Non-surgical, neurostimulation therapy
to restore swallowing control and reduce length of stay.

Targeting and restoring the neurological components of swallowing coordination and control that are disrupted due to brain injury or prolonged mechanical ventilation.

Dysphagia is Common, Costly,
and Harmful to Patients​

Dysphagia is Common, Costly, and Harmful to Patients​

Swallowing impairment, called dysphagia, affects millions of people worldwide and can have a profound health and economic impact.

Extended
Hospital Stay
High Burden
of Care
Poor Quality
of Life
Treating the Root Cause of Dysphagia.
Phagenyx® Neurostimulation System

​Introducing the first and only treatment using pharyngeal electrical stimulation (PES) to restore swallowing control, facilitate airway protection, and accelerate recovery.​

Personalized levels of PES, delivered at the earliest stages after injury, enhance neurorehabilitation and reorganization of swallowing control, while requiring minimal patient participation.

Video Duration: 02:40
Video Duration: 05:50

Simple & Safe

Non-surgical therapy with 10+ years of clinical use in Europe
1

Adjust the catheter to reflect patient anatomy and then insert. When ready to deliver treatment, connect the catheter to the Base Station.

2

Follow Base Station on-screen instructions to measure patient sensory capacity and optimize the stimulation level

3

Deliver optimized stimulation for 10 minutes once per day. On completion, disconnect the Base Station. Leave the catheter in place.

4

Repeat for 3-6 days as clinically indicated. On completion of the treatment regimen, remove the catheter or leave in place for feeding for up to 30 days

Extensive Clinical Evidence
Demonstrated Safety in Multiple Patient Populations
Years
0 +
Randomized
Control Trials
0 +
Publications
0 +
SEPTEMBER 5, 2024

|

Press Release

Phagenesis Appoints Chad Hoskins as Chief Executive Officer Following Recent Close of $42M Series D Financing

  • Accomplished leader brings strong track record of commercial expansion in the US
  • Company is focused on accelerating uptake of Phagenyx® to treat more patients in the US and Europe
  • Phagenyx® is a first-of-its-kind therapy using neurostimulation to restore swallowing control in patients with severe swallowing difficulties (dysphagia)

MANCHESTER, England, Sept. 5, 2024 /PRNewswire/ — Phagenesis, a pioneering company that has developed a first-of-its-kind neurostimulation system to treat swallowing dysfunction, today announced the appointment of Chad Hoskins as Chief Executive Officer (CEO). The seasoned executive brings decades of experience in scaling innovative MedTech therapies, driving commercial growth in the US and delivering on strategic objectives.

“We are extremely excited to have Chad join the company at this critical phase of growth as we build on our success in Europe and expand the use of Phagenyx® in the US,” said Oern Stuge, MD, Chairman of the Board of Directors, Phagenesis. “His relentless focus on improving patient care and deep experience in commercializing novel technologies will bolster the company’s efforts to bring our life-changing therapy to more patients in the US, Europe, and beyond.”

Founded in 2007, Phagenesis is committed to scientific and clinical excellence in the development of novel therapies to treat patients suffering from neurogenic dysphagia.
The foundational science and clinical evidence for the pharyngeal electrical stimulation used in Phagenyx, has been peer reviewed and published at the highest level.

CHAD HOSKINS

Chief Executive Officer

CONOR MULROONEY

Co-Founder & Chief Operating Officer

ANDRE NEL

Chief Financial Officer

SHAHEEN HAMDY

Co-Founder & Chief Scientific Officer

BORIS DEUTSCHMANN

Director European Sales

SCOTT GRANT

VP US Therapy Development

ANIL KENI

VP Global Marketing

CARI MANYPENNY

Head of Global Education

KATE ECKLUND

VP Clinical Affairs

OERN STUGE

Chairperson, Director

Chairperson Orsco Lifesciences AG
FRED EDENIUS

Director

Founder / Director Scientific Venture Partners
MICHEL GARDET

Director

Representing Nestle Health Sciences
DREW BURDON

Director

Partner EQT Lifesciences
MARK WYATT

Director

Investment Director Northern Gritstone
MICHAEL SJÖSTRÖM

Director

Co-founder / Partner Sectoral Asset Management
CHAD HOSKINS

Director

CEO Phagenesis
Get more information

For more information about Phagenesis or the Phagenyx System, please complete the form below.

Come work with us

We are looking for new talent to fuel our next stage of growth. If you are interested in joining our dynamic team, reach out to us at careers@phagenesis.com or view our open positions on LinkedIn.

Get more information

For more information about Phagenesis or the Phagenyx System, please complete the form below.

Come work with us

We are looking for new talent to fuel our next stage of growth. If you are interested in joining our dynamic team, reach out to us at jobs@phagenesis.com or view our open positions on LinkedIn.

Get more information

For more information about Phagenesis or the Phagenyx System, please complete the form below.

Come work with us

We are looking for new talent to fuel our next stage of growth. If you are interested in joining our dynamic team, reach out to us at jobs@phagenesis.com or view our open positions on LinkedIn.